Compare Abbott Laboratories (ABT) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Abbott Laboratories trades at $109.41 (market cap $187.95B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.34. The key difference: Abbott Laboratories pays a 2.32% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABT | TLT | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | — |
52-Week High | $136.62 | $92.06 |
52-Week Low | $82.57 | $82.05 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
TLT trades at $82.76, up 0.29% on the day, while technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and concerns about U.S. debt levels nearing $40 trillion. Recent institutional activity includes Ferguson Shapiro LLC purchasing 37,900 shares, indicating some professional interest despite the challenging environment.
The outlook remains cautious as rising oil prices and inflation concerns continue to pressure long-term bond yields higher. Investment opportunities exist for income-focused investors through TLT's dividend payments, but risks include Federal Reserve policy uncertainty and geopolitical tensions affecting Treasury markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
